Stanislovas Jankauskas

Dr. Stanislovas Jankauskas

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Gaetano SantulliGaetano Santulli
Gaetano Santulli
UKUrna Kansakar
Urna Kansakar
FVFahimeh Varzideh
Fahimeh Varzideh
PMPasquale Mone
Pasquale Mone
SJStanislovas Jankauskas
Stanislovas Jankauskas
ALAngela Lombardi
Angela Lombardi
Taurine, a naturally occurring sulfur-containing amino acid, has attracted significant attention in recent years due to its potential health benefits. Found in various foods and often used in energy drinks and supplements, taurine has been studied extensively to understand its impact on human physiology. Determining its exact functional roles represents a complex and multifaceted topic. We provide an overview of the scientific literature and present an analysis of the effects of taurine on various aspects of human health, focusing on aging and cardiovascular pathophysiology, but also including athletic performance, metabolic regulation, and neurological function. Additionally, our report summarizes the current recommendations for taurine intake and addresses potential safety concerns. Evidence from both human and animal studies indicates that taurine may have beneficial cardiovascular effects, including blood pressure regulation, improved cardiac fitness, and enhanced vascular health. Its mechanisms of action and antioxidant properties make it also an intriguing candidate for potential anti-aging strategies.

Verified
Journal Article
Open access
PDF file
IFImma Forzano
Imma Forzano
FVFahimeh Varzideh
Fahimeh Varzideh
RARoberta Avvisato
Roberta Avvisato
SJStanislovas Jankauskas
Stanislovas Jankauskas
PMPasquale Mone
Pasquale Mone
Gaetano SantulliGaetano Santulli
Gaetano Santulli
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. GIP and GLP1 are incretin hormones: they are released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity secreting insulin. GIP and GLP1 also have other metabolic functions. GLP1, in particular, reduces food intake and delays gastric emptying. Moreover, Tirzepatide has been shown to improve blood pressure and to reduce Low-Density Lipoprotein (LDL) cholesterol and triglycerides. Tirzepatide efficacy and safety were assessed in a phase III SURPASS 1–5 clinical trial program. Recently, the Food and Drug Administration approved Tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise, to achieve better glycemic blood levels in patients with diabetes. Other clinical trials are currently underway to evaluate its use in other diseases. The scientific interest toward this novel, first-in-class medication is rapidly increasing. In this comprehensive and systematic review, we summarize the main results of the clinical trials investigating Tirzepatide and the currently available meta-analyses, emphasizing novel insights into its adoption in clinical practice for diabetes and its future potential applications in cardiovascular medicine.

1 January 2011 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
Egor PlotnikovEgor Plotnikov
Egor Plotnikov
ACA.A. Chupyrkina
A.A. Chupyrkina
SJStanislovas Jankauskas
Stanislovas Jankauskas
IPI.B. Pevzner
I.B. Pevzner
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
DZD.B. Zorov
D.B. Zorov

7 July 2021 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
SJStanislovas Jankauskas
Stanislovas Jankauskas
Jessica GambardellaJessica Gambardella
Jessica Gambardella
Celestino SarduCelestino Sardu
Celestino Sardu
ALAngela Lombardi
Angela Lombardi
Gaetano SantulliGaetano Santulli
Gaetano Santulli
Substantial evidence indicates that microRNA-155 (miR-155) plays a crucial role in the pathogenesis of diabetes mellitus (DM) and its complications. A number of clinical studies reported low serum levels of miR-155 in patients with type 2 diabetes (T2D). Preclinical studies revealed that miR-155 partakes in the phenotypic switch of cells within the islets of Langerhans under metabolic stress. Moreover, miR-155 was shown to regulate insulin sensitivity in liver, adipose tissue, and skeletal muscle. Dysregulation of miR-155 expression was also shown to predict the development of nephropathy, neuropathy, and retinopathy in DM. Here, we systematically describe the reports investigating the role of miR-155 in DM and its complications. We also discuss the recent results from in vivo and in vitro models of type 1 diabetes (T1D) and T2D, discussing the differences between clinical and preclinical studies and shedding light on the molecular pathways mediated by miR-155 in different tissues affected by DM.

Verified
Journal Article
Open access
PDF file
FVFahimeh Varzideh
Fahimeh Varzideh
JGJessica Gambardella
Jessica Gambardella
UKUrna Kansakar
Urna Kansakar
SJStanislovas Jankauskas
Stanislovas Jankauskas
Gaetano SantulliGaetano Santulli
Gaetano Santulli
Embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of the blastocyst. ESCs have two distinctive properties: ability to proliferate indefinitely, a feature referred as “self-renewal”, and to differentiate into different cell types, a peculiar characteristic known as “pluripotency”. Self-renewal and pluripotency of ESCs are finely orchestrated by precise external and internal networks including epigenetic modifications, transcription factors, signaling pathways, and histone modifications. In this systematic review, we examine the main molecular mechanisms that sustain self-renewal and pluripotency in both murine and human ESCs. Moreover, we discuss the latest literature on human naïve pluripotency.

5 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
AAAyobami Adebayo
Ayobami Adebayo
FVFahimeh Varzideh
Fahimeh Varzideh
Scott Maxwell WilsonScott Maxwell Wilson
Scott Maxwell Wilson
Jessica GambardellaJessica Gambardella
Jessica Gambardella
MEMichael Eacobacci
Michael Eacobacci
Gaetano SantulliGaetano Santulli
Gaetano Santulli
L-Arginine is involved in many different biological processes and recent reports indicate that it could also play a crucial role in the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, we present an updated systematic overview of the current evidence on the functional contribution of L-Arginine in COVID-19, describing its actions on endothelial cells and the immune system and discussing its potential as a therapeutic tool, emerged from recent clinical experimentations.